Haloenol lactone: A new synergist of chemotherapy in vitro

Jiang Zheng, Gregory T. Wurz, Timothy B. Cadman, Michael W. Degregorio, Daniel A. Jones, Bruce D. Hammock

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Over-expression of glutathione S-transferases (GST) has been found to play a significant role in multiple drug resistance in cancer chemotherapy. To combat GST mediated drug resistance, GST inhibitors are being studied as potential synergists for effective cancer chemotherapy. We have designed and synthesized a haloenol lactone derivative as a mechanism-based inactivator of GST-Π isozyme. In the current study, we examined the inhibitory effect of the haloenol lactone compound on GST of a human renal carcinoma cell line UOK130 and found that this compound shows time-dependent GST inhibition in these cancer cells. The enzyme activity lost upon incubation with the haloenol lactone could not be restored by extensive dialysis against buffer. Pretreatment of the cancer cells with 1.0 μM of haloenol lactone increased cytotoxicity induced by cisplatin in the UOK130 cell line. This report further supports the possibility of synergizing alkylating agents in cancer chemotherapy by use of selective GST inhibitors.

Original languageEnglish (US)
Pages (from-to)13-17
Number of pages5
JournalBiochemical and Biophysical Research Communications
Volume241
Issue number1
DOIs
StatePublished - Dec 8 1997

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Fingerprint Dive into the research topics of 'Haloenol lactone: A new synergist of chemotherapy in vitro'. Together they form a unique fingerprint.

  • Cite this

    Zheng, J., Wurz, G. T., Cadman, T. B., Degregorio, M. W., Jones, D. A., & Hammock, B. D. (1997). Haloenol lactone: A new synergist of chemotherapy in vitro. Biochemical and Biophysical Research Communications, 241(1), 13-17. https://doi.org/10.1006/bbrc.1997.7762